VYNE Therapeutics (VYNE) EBIT Growth (3y) (2020 - 2026)
VYNE Therapeutics (VYNE) EBIT Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 13.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.40% |
| Jun 30, 2025 | 3.09% |
| Mar 31, 2025 | -1.90% |
| Dec 31, 2024 | -13.02% |
| Sep 30, 2024 | -6.73% |
| Jun 30, 2024 | -2.90% |
| Mar 31, 2024 | 8.89% |
| Dec 31, 2023 | 32.27% |
| Sep 30, 2023 | 35.74% |
| Jun 30, 2023 | 60.48% |
| Mar 31, 2023 | 47.19% |
| Dec 31, 2022 | 40.25% |
| Sep 30, 2022 | 26.18% |
| Jun 30, 2022 | 24.63% |
| Mar 31, 2022 | 18.21% |
| Dec 31, 2021 | 38.91% |
| Sep 30, 2021 | 7.72% |
| Jun 30, 2021 | -1.32% |
| Mar 31, 2021 | 9.63% |
| Dec 31, 2020 | -32.39% |